Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Two key proteins that control heart growth identified
Researchers have identified how two proteins control the growth of the heart and its adaptation to high blood pressure that can help design new strategies to treat heart failure caused by excessive growth of the heart.
- Read more about 60 genetic disorders cause skin and nervous system problems
There are 60 genetic disorders that affect skin and nervous system in humans, researchers report.

[adsense:336x280:8701650588]
- Read more about Scientists grow new cartilage tissue from cow knee joint cells
A team of Swedish researchers has used cells from cow knee joints to grow new cartilage tissue in laboratory that can help treat degenerative joint disease like osteoarthritis (OA).
- Read more about DCGI took strict measures on opthalmic drug Avastin
Drugs Controller General India (DCGI) took strict measures on Roche's Avastin (Bevacizumab Injection) after some reports on loss of visions. It is noted that opthalmic injection of Avastin leads to blindness in some patients which is not approved for intra-vitrieal use in India as per DCGI.
- Read more about Mankind enters in US market
Indian pharmaceutical company Mankind Pharma entered into the US market with starting investment of Rs. 300 crore. Mankind Pharma step up to be a multinational pharma company
- Read more about Human antibodies from survivors to kill Ebola viruses
In what could be termed as “silver bullet” for Ebola viruses, a team of researchers has isolated human antibodies from Ebola survivors which can neutralise multiple species of the virus that has killed more than 11,000 people in West Africa in the past two years.
- Read more about AbbVie's Venetoclax receives breakthrough therapy designation from FDA in combination with Rituximab
AbbVie , a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein being developed by AbbVie in partnership with Genentech and Roche.
- Read more about CymaBay Therapeutics announces successful completion of End-of-Phase 2 discussions with FDA for Arhalofenate
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, announced that it has successfully concluded its end-of-phase 2 meeting discussions with the U.S. Food and Drug Administration (FDA) on the Phase 3 development program for arhalofenate.
- Read more about NextSource Biotechnology gains FDA approval for new 5 mg strength of Gleostine® (Lomustine), an Anti-Cancer Chemotherapy Agent
NextSource Biotechnology, LLC announced that Gleostine® (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the United States.
- Read more about Oncolytics Biotech® Inc. announces first patients treated in Phase 1b study in advanced Pancreatic Cancer
Oncolytics Biotech Inc. ("Oncolytics") announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).